Browse News
Filter News
Found 69 articles
-
InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets
12/9/2023
Cipla Limited announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level.
-
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
10/11/2022
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previously announced underwritten public offering of 3,636,365 common and pre-funded units.
-
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
10/7/2022
Avenue Therapeutics, Inc., a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, announced the pricing of its underwritten public offering of 3,636,365 common and pre-funded units.
-
Innovative Cellular Therapeutics Appoints Lucy Lu as Chief Operations Officer
4/6/2022
Innovative Cellular Therapeutics, a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor T cell therapies with a focus on solid tumors, announced the appointment of Lucy Lu, M.D. as Chief Operations Officer.
-
Amlodipine Besylate Market Size, Industry Statistics, Growth Potentials, Trends, Company Profile, Global Expansion Strategies by Top Key Vendors Till 2027
2/17/2022
The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.
-
Traumatic Brain Injury Drugs Market is Likely to Experience a Tremendous Growth in Near Future 2018-2026
12/7/2021
Traumatic brain injury can be defined as injury to the brain caused due to a blow or jolt to the head resulting in damage to the brain cells and blood vessels.
-
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
5/16/2021
Fortress Biotech, Inc., an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced financial results and recent corporate highlights for the first quarter ended March 31, 2021.
-
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV TramadolThe FDA Has Not Provided a Decision Regarding the NDA
4/13/2021
Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced that the U.S. Food and Drug Administration was still reviewing its New Drug Application for IV tramadol and had not provided a decision regarding the NDA.
-
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights
3/31/2021
Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the Zydus Group, signed a Development and Asset Purchase Agreement for CUTX-101 for the treatment of Menkes disease
-
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
2/22/2021
Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer.
-
Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences
1/5/2021
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Details of the events are as follows: 10
-
Avenue Therapeutics Provides Regulatory Update for IV TramadolCompany Anticipates NDA Resubmission in February 2021
12/17/2020
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol. Avenue had requested this Type A meeting to address a Complete Response Letter (CRL) it received fro
-
Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
12/15/2020
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation to Cyprium Therapeutics (“Cyprium”) for CUTX-101, a potential treatment for Menkes disease. Often lethal
-
Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row
11/18/2020
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and ene
-
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
11/9/2020
Product revenue for the first nine months of 2020 increased 29 % year-over-year to $ 30.8 million R olling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter of 2021 and be completed by the end of the second quarter of 2021
-
Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual MeetingClinical data on CAEL-101 for AL amyloidosis and MB-106 CD20-targeted CAR T cell therapy to be presented
11/4/2020
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that data from two of its clinical programs have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5 – 8, 2020
-
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners
10/19/2020
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Scott Henry, Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research at ROTH Capital Partners, will host a webinar with the management team of Journey Medical Corporation
-
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV TramadolManagement to Host Conference Call at 8:30 a.m. ET
10/12/2020
Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Company’s New Drug Application for IV tramadol.
-
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
9/14/2020
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that Caelum Biosciences, Inc. (“Caelum”), in collaboration with Alexion Pharmaceuticals, Inc. (“Alexion”), initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101,
-
Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences
9/10/2020
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020. The company will also host virtual one-on-o